Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937971 | 0.86 | ALDH1A1 (0.61) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL13750063 | 0.84 | TSHR (0.44) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL29952852 | 0.82 | KDM4E (0.51) | SMN1; SMN2TSHRCASP1ALDH1A1KDM4E | |
| SCHEMBL16971638 | 0.79 | ABL1 (0.62) | SMN1; SMN2CASP1ALDH1A1CA1CA2 | |
| SCHEMBL28674119 | 0.79 | KDM4E (0.50) | SMN1; SMN2TSHRALDH1A1TP53CA1 | |
| SCHEMBL2065197 | 0.78 | CSNK2A1 (0.53) | SMN1; SMN2ALDH1A1CA1CA2MYC | |
| SCHEMBL1000440 | 0.76 | ALDH1A1 (0.71) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL9938748 | 0.76 | KEAP1 (0.50) | TSHRALDH1A1CA1CA2KDM4E | |
| SCHEMBL12590922 | 0.75 | ALDH1A1 (0.53) | SMN1; SMN2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL29950984 | 0.75 | GABRA1 (0.43) | SMN1; SMN2TSHRCASP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276007-A1 | CARBAMOYLPHENYLBORONIC ACID-CONTAINING ACRYLIC MONOMERS AND USES THEREOF | ALCON INC (CH) | 2025-09-04 | — | — | US | disclosed |
| US-20250277076-A1 | MUCOADHESIVE HYDROPHILIC COPOLYMERS AND USES THEREOF | ALCON INC (CH) | 2025-09-04 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| EP-2582680-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| CN-102947274-A | Biphenyl substituted 1, 3-dihydro-benzoimidazol-2-ylideneamine derivatives | NOVARTIS AG | 2013-02-27 | — | — | CN | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011157787-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276007-A1 | CARBAMOYLPHENYLBORONIC ACID-CONTAINING ACRYLIC MONOMERS AND USES THEREOF | ADCY6, ADCY1, ADCY7 | SMN1; SMN2 4467/4885TSHR 2199/4885CASP1 3690/4885 |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | SMN1; SMN2 1323/4885TSHR 4621/4885CASP1 35/4885 |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | SMN1; SMN2 552/4885TSHR 100/4885CASP1 1869/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | SMN1; SMN2 3850/4885TSHR 1345/4885CASP1 840/4885 |
| US-20250277076-A1 | MUCOADHESIVE HYDROPHILIC COPOLYMERS AND USES THEREOF | MUC1, TAS2R42, TAS2R41 | SMN1; SMN2 4382/4885TSHR 921/4885CASP1 3000/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | SMN1; SMN2 3850/4885TSHR 1345/4885CASP1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.